

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal TA494; Naltrexone–bupropion for managing overweight and obesity

Stakeholder List of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Orexigen Therapeutics (Naltrexone–bupropion) • Nalpropion Pharmaceuticals (Naltrexone–bupropion) <p><u>Patient Groups</u></p> <ul style="list-style-type: none"> • BEMDA: Black and Ethnic Minority Diabetes Association • Black Health Agency • Blood Pressure UK • British Cardiac Patients Association • British Obesity Society • Cardiovascular Care Partnership UK • Diabetes Research & Wellness Foundation • Diabetes UK • HEART UK • HOOP UK • InDependent Diabetes Trust • National Obesity Forum • Network of Sikh Organisations • Overeaters Anonymous • South Asian Health Foundation • Specialised Healthcare Alliance • Weight Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity • Association of British Clinical Diabetologists • British Association for Nursing in Cardiac Care • British Cardiovascular Intervention Society • British Cardiovascular Society • British Dietetic Association 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Actavis (orlistat) • Almus pharmaceuticals (orlistat) • GlaxoSmithKline (orlistat, bupropion) • Roche (orlistat) • Teva UK (orlistat) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cochrane Heart Group • Cochrane Metabolic & Endocrine Disorders Group

<ul style="list-style-type: none"> • British Geriatrics Society • British Heart Foundation • British and Irish Hypertension Society • British Nutrition Foundation • Faculty of Public Health Medicine • National Centre for Eating Disorders • National Diabetes Nurse Consultant Group • Primary Care Diabetes Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Endocrinology • Society for Vascular Technology and of Great Britain and Ireland • Society of Vascular Nurses • The Nutrition Society • The Obesity Management Association • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bromley CCG • NHS England • NHS North Durham CCG • Welsh Government 	<ul style="list-style-type: none"> • Cochrane Vascular • Cochrane Public Health Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.